What"s Ahead For Axsome Therapeutics?
What"s Ahead For Axsome Therapeutics?.....»»
Axsome Therapeutics price target raised to $186 from $165 at Ladenburg
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics price target raised to $200 from $145 at SunTrust
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why This Alzheimer’s Study Could Be Huge
As there is currently no FDA-approved treatment for Alzheimer’s agitation, any progress here could be lucrative. Axsome Therapeutics has announced a big step forward in its midstage Alzheimer’s study.....»»
Axsome Therapeutics to hold a pharmaceutical update conference call
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics initiated with an Outperform at Cowen
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics participates in a conference call with SunTrust
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics: AXS-07 achieves both co-primary endpoints in Phase 3 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Why Axsome Shares Are Pulling Back After A Clinical Readout
Shares of Axsome Therapeutics Inc (NASDAQ: AXSM) — which skyrocketed 3,565% in 2019 thanks to a steady stream of positive clinical updates &md read more.....»»
Axsome Therapeutics: AXS-05 met key secondary endpoints in STRIDE-1 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics accelerates completion of ADVANCE-1 Phase 2/3 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics Enters Oversold Territory (AXSM)
Dividend Channel.....»»
Axsome Therapeutics expects cash to fund operations for at least two years
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics announces anticipated milestones
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics reports Q4 EPS (71c), consensus (48c)
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Citi starts Prevail Therapeutics with Buy ahead of first clinical data
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics promotes Mark Jacobson to COO
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Jefferies starts Denali Therapeutics at Buy ahead of "lots of catalysts in 2020"
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics completes patient enrollment in INTERCEPT Phase 3 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Axsome Therapeutics completes patient randomization in STRIDE-1 Phase 3 trial
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»